1. Home
  2. TMC vs IMNM Comparison

TMC vs IMNM Comparison

Compare TMC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TMC the metals company Inc.

TMC

TMC the metals company Inc.

HOLD

Current Price

$4.29

Market Cap

2.1B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$26.17

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMC
IMNM
Founded
2011
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
TMC
IMNM
Price
$4.29
$26.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$8.85
$32.80
AVG Volume (30 Days)
6.9M
956.7K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
232.00
51.40
EPS
0.19
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
$23.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.40
$8.93
52 Week High
$11.35
$30.06

Technical Indicators

Market Signals
Indicator
TMC
IMNM
Relative Strength Index (RSI) 47.59 47.75
Support Level $4.24 $19.28
Resistance Level $4.81 $27.14
Average True Range (ATR) 0.32 1.10
MACD -0.04 -0.41
Stochastic Oscillator 34.57 9.58

Price Performance

Historical Comparison
TMC
IMNM

About TMC TMC the metals company Inc.

TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: